Ianalumab acts against B cells, white blood cells in the immune system, when they overreact and mistakenly attack the patient's own body. By blocking signals that these B cells need to grow and ...

The novel agent, along with standard second-line therapy, may allow patients to stay off treatment for longer periods and may ...

More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal ...

Key Takeaways An experimental drug can help many with a rare autoimmune bleeding conditionMore than half of people with immune thrombocytopenia wound up with healthy platelet levels after treatment ...

Ianalumab, which has already succeeded in testing against Sjogren’s syndrome, proved impactful in a condition that causes low ...

Novartis is divulging details from ianalumab’s summertime | Novartis is divulging details from ianalumab’s phase 3 win in a rare autoimmune blood disorder, and the data suggest the treatment could del ...

The addition of ianalumab to eltrombopag significantly improved outcomes for patients with pretreated primary immune ...

ITP is an autoimmune condition where the body’s immune cells mistakenly attack platelets, the blood cells responsible for clotting.

More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal antibody ianalumab for primary immune thrombocytopenia were able to maintain safe ...

Qihan's QT-019B program is supported by IND clearance for rSLE from both the US FDA and the China NMPA. The FDA has also granted Fast Track Designation for the SLE-ITP indication. Phase 1 enrollment ...

An experimental monoclonal antibody called ianalumab had promising results for more than half of patients with primary immune thrombocytopenia enrolled in a phase 3 trial, according to data published ...

Immune thrombocytopenia (ITP) is an autoimmune disorder characterised by both antibody-mediated platelet destruction and impaired megakaryocyte function. This results in decreased platelet counts and ...